AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02554045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
Study NCT00305669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study NCT00305669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00305669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunological diagnostic method
Study NCT00305669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00305669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00305669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT04584840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Same guidelines as group 1 (non-surgical) plus surgical treatment according to the following protocol:~Specific protocol for surgical treatment~* Wide mucoperiosteal flaps and complete surgical excision of necrotic bone together with a mucosa margin of at least 2 mm.~* Removal of dental pieces included in the diseased area and regularization of bony margins avoiding leaving sharp edges or spicules.~* Secure a two layered waterproof closure without tension (simple or with local flaps).~* Samples will be sent for Pathological and microbiological analysis.~* Stitches removal after two weeks~* Postoperative systemic antibiotic following the mentioned protocol until stitches removal.
Study NCT03643510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles.
Study NCT03643510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28.
Study NCT02259400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NSIPPV
Description: In N-SIPPV, the physician will set : an initial PEEP of 4-6 cmH20; a peak inspiratory pressure (PIP) of 15-20 cmH2O ; an inspiratory time (IT) of 0.3-0.4 seconds; a flow rate of 6-10 L/min and a respiratory rate (RR) of 40 bpm with the lowest FiO2 to maintain a oxygen saturation (SpO2) of 88-93%. Weaning from N-SIPPV will be performed with a reduction of the RR to 15 bpm with a PIP of 10-15 cmH2O and PEEP of 4 cmH2O and will be stopped when the baby will not show signs of RDS and with a fraction of inspired oxygen (FiO2)\< 0.3.
Study NCT02259400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP
Description: In BiPAP, the physician will set : an initial low CPAP-level of 4-6 cmH20 and high CPAP-level of 8-9 cmH20; a time high of 1 second and a pressure exchange rate of 20 bpm, with the lowest FiO2 to maintain a SpO2 of 88-93%. Weaning will start with a progressive reduction of the set pressure exchange rate ( minimum 15 pressures exchange/min), followed by the reduction of the higher level-CPAP down to 6 cmH20 and lower level-CPAP down to 4 cmH20. BiPAP will be stopped when the baby will not show signs of RDS and with a FiO2 \< 0.3.
Study NCT03570775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleeping bag phototherapy
Description: This device has a LED light emitter that incorporates one fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. The phototherapy sleeping bag is conceived with the aim of increasing the surface of phototherapy by means of a double exposure: ventral and dorsal, which allows the insertion of two phototherapy devices of 20x30 centimeters. The ventral and dorsal caps incorporate mesh optical fibers that are connected to the light emitter, in which the phototherapy time can be programmed. The fiber optic meshes are protected by a vinyl cover and a disposable lining for patient comfort and hygiene.
Study NCT03570775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional phototherapy
Description: This is a phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated. The device has a minimum height of 106 cm and a maximum of 152 cm, a depth of 64 cm and a width of 72 cm. The manufacturer recommends not using the lamp at distances of less than 50 cm because, although the heat radiation is minimal, this can influence distances less than 50 cm when the child is also exposed to infrared thermal radiation, typical of the servo cribs It is recommended to control temperature and eye protection due to the risk of ophthalmic injury from light, since the intensity of the light is concentrated in a single point.
Study NCT03735407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan procedure
Description: The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.~o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,
Study NCT00697593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)
Description: Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
Study NCT01158742 — intervention group
Intervention type: OTHER
Intervention: Glomerular Filtration Rate with Iothalamate
Description: used to determine kidney function
Study NCT01158742 — intervention group
Intervention type: OTHER
Intervention: Glomerular Filtration Rate with Iohexol
Description: used to determine kidney function
Study NCT00812175 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Systemic oral therapy according to product information
Study NCT01867515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic distortion of speech
Study NCT03419117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: An ESP block will be performed prior to surgery for postoperative pain control
Study NCT03419117 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A sham ESP block will be performed before surgery in the placebo group
Study NCT00926757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir prophylaxis
Description: Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
Study NCT00926757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic entecavir
Description: Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
Study NCT01214668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle.~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met.
Study NCT01214668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: 40 mg/m² on Day 1, given intravenously of each 28-day cycle~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met.
Study NCT01637714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotics
Description: * B. longum BORI: 1 x 109~* B. bifidum BGN4: 1 x 109~* B. lactis AD011: 1 x 109~* B. infantis IBS007: 1 x 109~* Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water
Study NCT01637714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water
Study NCT03489252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Wear Fitbit Charge 3
Study NCT01308034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: All patients will be treated with sunitinib (2 dose levels) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.~Dose level 1 : 25 mg once daily Dose level 2 : 37.5 mg once daily Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring.
Study NCT04217460 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention for fluency difficulty
Description: Children are required to speak materials they hear on recordings. The materials are not words, but contain sound sequences that occur in their language and English.
Study NCT04217460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for fluency difficulty
Description: Children are required to speak materials they hear on recordings. The materials are not words, but contain sound sequences that occur in their language and English.
Study NCT03574077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instant Messaging (IM)
Description: Tailored automatic, fix- scheduled regular messages will be sent and counselors will interact with smokers in the intervention group through WhatsApp since initial contact and until 2-month after baseline. The interaction will follow the principle of Motivational Interviewing, which will focus on enabling change through the enhancement of intrinsic motivation and the exploration and resolution of ambivalence. Counsellors will identify discrepancies between participants' thought and their action, support their autonomy, be empathetic towards the participant, avoid confrontation, and adjust to resistance. Any smokers who do not use IM or refuse to receive IM messages will be contacted via SMS messages or telephone calls. For smokers who do not respond to regular messages, 3 additional prompt messages will be sent in the 1st month to initiate a conversation.
Study NCT03574077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.
Study NCT03574077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AWARD advice
Description: AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.
Study NCT04078568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
Study NCT04078568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: IVIG at a single dose of 2 g/kg, with the maximum dose of 60g
Study NCT04078568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
Study NCT04078568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.
Study NCT04078568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
Study NCT04290663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systematic RAI-treatment
Description: Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation
Study NCT04290663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision of RAI-treatment guided by a post-operative assessment
Description: The decision-making for the administration of an adapted RAI-treatment will be taken according to the following criteria:~* No RAI treatment if Tg/LT4 ≤1 ng/mL and rhTSH-sTg ≤10 ng/mL and normal diagnostic RAI-scintigraphy~* 1.1 GBq after rhTSH if Tg/LT4>1 ng/mL or rhTSH-sTg>10 ng/mL and normal diagnostic RAI-scintigraphy.~* 3.7 GBq after rhTSH if metastatic lymph-node(s) detected on diagnostic RAI-scintigraphy without distant metastasis~* 3.7 GBq after hormone withdrawal if distant metastasis detected on diagnostic RAI-scintigraphy or on the hybrid CT scan of the SPECT-CT acquisition
Study NCT03707808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intratumoral injection of autologous CD1c (BDCA-1)+ myDC
Description: intratumoral injections plus intravenous administration
Study NCT03707808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intratumoral injection of ipilimumab and AS01b
Description: Intratumoral injection of ipilimumab and AS01b
Study NCT03707808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of ipilimumab and AS01b
Description: Intratumoral injection of ipilimumab and AS01b
Study NCT03707808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV nivolumab
Description: Nivolumab administered intravenously
Study NCT03707808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV nivolumab
Description: Nivolumab administered intravenously
Study NCT03574077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NRT sampling
Description: One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.
Study NCT03574077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NRT sampling
Description: One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.
Study NCT03574077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active referral
Description: SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.
Study NCT03574077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active referral
Description: SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.
Study NCT03574077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS messaging
Description: All smokers will receive fix-schedule general messages on SC through short message service (SMS) since their initial participation until 2-month after baseline. These messages include: (a) brief health warning, (b) benefit of quitting, (c) methods to quit and to cope with craving, and (d) SC services and their effectiveness. General SC messages will be sent twice per week in the 1st month and once per week in the 2nd month after joining this study.
Study NCT03343743 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oligomineral water
Description: Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C \<200 mg/L) for at least 12 months
Study NCT00649077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Tablets 15 mg
Description: 15mg, single dose fasting
Study NCT00649077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic® Tablets 15 mg
Description: 15mg, single dose fasting
Study NCT03045653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Oral Product
Description: Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
Study NCT04106908 — intervention group
Intervention type: BIOLOGICAL
Intervention: Eqwilate
Description: Eqwilate® is a new generation, albumin-free, high-purity, double virus-inactivated, freezedried concentrate of VWF and FVIII
Study NCT01724177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg of Lenalidomide administered orally once daily
Study NCT00370591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate and fluticasone propionate
Study NCT01781104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Description: Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
Study NCT01781104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered subcutaneously once daily for 14 days.
Study NCT01624480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
Study NCT03853031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LVEDA cm2 guided intraoperative fluid in TEE /Study Group
Description: Placement of Transoesophageal echocardiography probe in TEE group to measure Left ventricular end diastolic area cm2
Study NCT03853031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVP guided intraoperative fluid in CVP / Control group
Description: Ultrasound guided Internal Jugular Vein catheter placement in CVP group to measure CVP value cms H2O .
Study NCT03421340 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DSC
Description: Stone removal without fluoroscopy using the SpyGlass device.
Study NCT03421340 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ERC
Description: Standard of care stone removal with fluoroscopy.
Study NCT02635919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mSMART
Description: A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
Study NCT01986803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point.
Study NCT03298945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miralax-Gatorade Prep
Description: 2-L split-dose Miralax-Gatorade bowel prep for colonoscopy
Study NCT03298945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely
Description: 4-L split dose Golytely is the current standard prep at the VA
Study NCT01820611 — intervention group
Intervention type: DEVICE
Intervention: Arcos Revision Stem System
Description: Revision Hip System